LLAI Stock Overview
A diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LungLife AI, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.14 |
| 52 Week High | UK£1.42 |
| 52 Week Low | UK£0.13 |
| Beta | -0.28 |
| 11 Month Change | -15.29% |
| 3 Month Change | -53.55% |
| 1 Year Change | -58.86% |
| 33 Year Change | -92.82% |
| 5 Year Change | n/a |
| Change since IPO | -92.98% |
Recent News & Updates
Recent updates
We Think LungLife AI (LON:LLAI) Needs To Drive Business Growth Carefully
Dec 08
We Think LungLife AI (LON:LLAI) Needs To Drive Business Growth Carefully
Aug 12Here's Why LungLife AI (LON:LLAI) Must Use Its Cash Wisely
Feb 09Here's Why We're A Bit Worried About LungLife AI's (LON:LLAI) Cash Burn Situation
Oct 08Shareholder Returns
| LLAI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.7% | -3.7% | 0.06% |
| 1Y | -58.9% | -27.8% | 5.7% |
Return vs Industry: LLAI underperformed the UK Biotechs industry which returned -27.8% over the past year.
Return vs Market: LLAI underperformed the UK Market which returned 5.7% over the past year.
Price Volatility
| LLAI volatility | |
|---|---|
| LLAI Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: LLAI's share price has been volatile over the past 3 months.
Volatility Over Time: LLAI's weekly volatility has decreased from 16% to 7% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 15 | Paul Pagano | lunglifeai.com |
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019.
LungLife AI, Inc. Fundamentals Summary
| LLAI fundamental statistics | |
|---|---|
| Market cap | UK£4.41m |
| Earnings (TTM) | -UK£4.18m |
| Revenue (TTM) | UK£35.53k |
124.2x
P/S Ratio-1.1x
P/E RatioIs LLAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLAI income statement (TTM) | |
|---|---|
| Revenue | US$46.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$46.00k |
| Other Expenses | US$5.46m |
| Earnings | -US$5.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -11,767.39% |
| Debt/Equity Ratio | 0% |
How did LLAI perform over the long term?
See historical performance and comparison